SCHEMBL18907926

SCHEMBL18907926

Cc1cc(F)ccc1OCC1COC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
GLA P06280 1/20 0.45
HTR2A P28223 2/20 0.44
HTR2C P28335 2/20 0.44
HTR2B P41595 2/20 0.44
SSTR4 P31391 1/20 0.42
GRM5 P41594 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
NOTUM Q6P988 1/20 0.39
PIK3CG P48736 2/20 0.38
PIK3CA P42336 1/20 0.38
RBP4 P02753 1/20 0.38
SLC6A4 P31645 4/20 0.37
MKNK2 Q9HBH9 1/20 0.37
SLC6A2 P23975 3/20 0.37
BRD4 O60885 1/20 0.36
SLC6A3 Q01959 2/20 0.36
MCHR1 Q99705 1/20 0.36
DRD4 P21917 1/20 0.36
NTRK1 P04629 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17111325 0.84 DRD4 (0.46) HTR2AHTR2CHTR2BSLC6A4SLC6A2
SCHEMBL19289461 0.84 HPGD (0.46) ALDH1A1GLA
SCHEMBL24224805 0.83 HPGD (0.49) HTR2AHTR2CHTR2BSSTR4MRGPRX4
SCHEMBL31710828 0.81 PKM (0.49) ALDH1A1HTR2AHTR2CHTR2BGRM5
SCHEMBL15627275 0.81 HTR2C (0.44) ALDH1A1GLAHTR2AHTR2CHTR2B
SCHEMBL18907906 0.81 HTR2A (0.41) HTR2AHTR2CHTR2BGRM5RBP4
SCHEMBL18964615 0.80 ALDH1A1 (0.69) ALDH1A1GLANOTUMBRD4
SCHEMBL22283687 0.80 SSTR4 (0.44) ALDH1A1GLAHTR2AHTR2CHTR2B
SCHEMBL22283689 0.80 SSTR4 (0.44) ALDH1A1GLAHTR2AHTR2CHTR2B
SCHEMBL15906056 0.76 MAPK14 (0.47) ALDH1A1GLASSTR4DRD4NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166584-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2017-06-15 US disclosed
US-20170166583-A1 ESTER ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2017-06-15 US disclosed
US-20170166582-A1 PYRAZOLE ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2017-06-15 US disclosed
WO-2017091617-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC (US) 2017-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166583-A1 ESTER ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ALDH1A1 180/4885GLA 693/4885HTR2A 4837/4885
US-20170166582-A1 PYRAZOLE ACC INHIBITORS AND USES THEREOF ACACA, ACACB, PC ALDH1A1 185/4885GLA 1668/4885HTR2A 4800/4885
US-20170166584-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT1 ALDH1A1 203/4885GLA 1666/4885HTR2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.